Research Reports
Hemophilia Market Size To Reach USD 16.84 Billion By 2026 – Reports and Data
Hemophilia Market Size To Reach USD 16.84 Billion By 2026 – Reports and Data
Published by news degree
Posted on August 3, 2021
Home > Research Reports > Hemophilia Market Size To Reach USD 16.84 Billion By 2026 – Reports and Data
Rising incidences of hemophilia, increasing awareness, technological advancements, strategic developments by key market players such as partnerships and mergers and acquisitions, favorable research and developments are the key factors propelling the hemophilia market.
According to the current analysis of Reports and Data, the global Hemophilia market was valued at USD 11.10 Billion in 2018 and is expected to reach USD 16.84 Billion by the year 2026, at a CAGR of 5.4 percent. Hemophilia is a rare genetic disorder in which blood doesn’t clot normally because it lacks sufficient blood-clotting proteins known as clotting factors. Among the types of disorders, type A is anticipated to be multiple times more predominant than type B. The global market for hemophilia drugs is growing significantly, owing to the increasing number of hemophilic patients globally. Hemophilia medications are turning out to be one of the essential medicinal products to confine the loss of blood as there is no exact treatment accessible to treat this disorder. Strategies such as geographical expansion by the key market players and new product development are expected to have the most impact on the Hemophilia market. Rising prevalence of the disorder, a significant focus of key market players on the development of gene therapy mechanism, increasing awareness about the disorder, and favorable regulatory scenario, are some of the key factors that support the market growth in the industry.
However, lack of availability of medicine and high cost of treatment are the factors that limit the market growth over the globe during 2019-2026.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2249
Further key findings from the report suggest
- Launch of products for hemophilia treatment is expected to support the market growth during the coming years. For instance, in May 2018 FDA approved Roche’s Hemlibra for treatment of hemophilia with or without inhibitors.
- North America dominates the regional hemophilia market and held around 48% market share in 2018.
- Hemophilia B is projected to be the fastest growing segment at a CAGR of 5.7%. However, low availability of treatment for the segment is a major challenge for the market growth for this segment.
- Asia Pacific is expected to show a high growth rate in the hemophilic market and will grow at a CAGR of 6%
- Recombinant coagulation factor concentrate and plasma coagulation factor concentrate are the common options to treat hemophilia and are expected to take up an important position in the global hemophilia market owing to increased prevalence of the von Willebrand Disease.
- On-demand treatment segment is expected to grow at a CAGR of 5.6%.
- Treatment for hemophilia is in the clinical pipeline stage. And the multiple treatments that are underway are expected to significantly improve the quality of life of patients suffering from hemophilia.
- Availability of treatment and lack of awareness about hemophilia is likely to hinder the market growth during the forecast period.
- Key participants include Shire (Takeda), Bayer Healthcare, CSL Behring, Novo Nordisk, Sanofi, Pfizer Inc., among others.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2249
For the purpose of this report, Reports and Data has segmented the Hemophilia market on the basis of type, product type, treatment type, therapy type, and region:
Type (Revenue, USD Million; 2016–2026)
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Product (Revenue, USD Million; 2016–2026)
- Plasma derived coagulation factor concentrates
- Factor VIII
- Factor IX
- Factor XII
- Activated prothrombin complex concentrate
- Von Willebrand factor
- Recombinant coagulation factor concentrates
- Factor VIII
- Factor IX
- Von Willebrand factor
- Desmopressin
- Antifibrinolytic agents
- Others
Treatment Type (Revenue, USD Million; 2016–2026)
- Prophylactic
- On-Demand
Therapy Type (Revenue, USD Million; 2016–2026)
- Replacement Therapy
- Immune Tolerance Induction Therapy
- Gene Therapy
Regional Outlook (Revenue in USD Million; 2016–2026)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- The Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt
- Latin America
- Brazil
- Mexico
- Argentina
- Columbia
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2249
Key Questions Answered by the Report:
- What are the key growth driving and restraining factors of the Hemophilia market?
- What are key opportunities and growth prospects of the Hemophilia industry is expected to witness over the forecast period?
- Who are the prominent players operating in the market? What are the key strategies adopted by these companies?
- Which region is expected to dominate the market growth over the forecast period?
- Which segments are expected to register lucrative growth over the forecast period?
- What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?
Thank you for reading our report. Please connect with us to know more about the report or for requesting customization of the report. Our team will ensure the report is best suited to meet your requirements.
Explore Reports and Data’s Prime Analysis of the global Healthcare & Pharmaceutical Industry:
Diabetes Injection Pens Market @ https://www.google.sc/url?q=https://www.reportsanddata.com/report-detail/diabetes-injection-pens-market
Artificial Pancreas Device System (APDS) Market @ https://www.google.ms/url?q=https://www.reportsanddata.com/report-detail/artificial-pancreas-device-system-apds-market
Disposable Laparoscopic Instruments Market @ https://www.google.gy/url?q=https://www.reportsanddata.com/report-detail/disposable-laparoscopic-instruments-market
Recombinant Human Serum Albumin Market @ https://www.google.nu/url?q=https://www.reportsanddata.com/report-detail/recombinant-human-serum-albumin-market
Healthcare RCM Outsourcing Market @ https://www.google.fr/url?q=https://www.reportsanddata.com/report-detail/healthcare-rcm-outsourcing-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Read Full Press Release: https://www.reportsanddata.com/press-release/global-hemophilia-market
The post Hemophilia Market Size To Reach USD 16.84 Billion By 2026 – Reports and Data first appeared on News Degree | Hub for Latest and Trending News from Around the Globe.
Rising incidences of hemophilia, increasing awareness, technological advancements, strategic developments by key market players such as partnerships and mergers and acquisitions, favorable research and developments are the key factors propelling the hemophilia market.
According to the current analysis of Reports and Data, the global Hemophilia market was valued at USD 11.10 Billion in 2018 and is expected to reach USD 16.84 Billion by the year 2026, at a CAGR of 5.4 percent. Hemophilia is a rare genetic disorder in which blood doesn’t clot normally because it lacks sufficient blood-clotting proteins known as clotting factors. Among the types of disorders, type A is anticipated to be multiple times more predominant than type B. The global market for hemophilia drugs is growing significantly, owing to the increasing number of hemophilic patients globally. Hemophilia medications are turning out to be one of the essential medicinal products to confine the loss of blood as there is no exact treatment accessible to treat this disorder. Strategies such as geographical expansion by the key market players and new product development are expected to have the most impact on the Hemophilia market. Rising prevalence of the disorder, a significant focus of key market players on the development of gene therapy mechanism, increasing awareness about the disorder, and favorable regulatory scenario, are some of the key factors that support the market growth in the industry.
However, lack of availability of medicine and high cost of treatment are the factors that limit the market growth over the globe during 2019-2026.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2249
Further key findings from the report suggest
- Launch of products for hemophilia treatment is expected to support the market growth during the coming years. For instance, in May 2018 FDA approved Roche’s Hemlibra for treatment of hemophilia with or without inhibitors.
- North America dominates the regional hemophilia market and held around 48% market share in 2018.
- Hemophilia B is projected to be the fastest growing segment at a CAGR of 5.7%. However, low availability of treatment for the segment is a major challenge for the market growth for this segment.
- Asia Pacific is expected to show a high growth rate in the hemophilic market and will grow at a CAGR of 6%
- Recombinant coagulation factor concentrate and plasma coagulation factor concentrate are the common options to treat hemophilia and are expected to take up an important position in the global hemophilia market owing to increased prevalence of the von Willebrand Disease.
- On-demand treatment segment is expected to grow at a CAGR of 5.6%.
- Treatment for hemophilia is in the clinical pipeline stage. And the multiple treatments that are underway are expected to significantly improve the quality of life of patients suffering from hemophilia.
- Availability of treatment and lack of awareness about hemophilia is likely to hinder the market growth during the forecast period.
- Key participants include Shire (Takeda), Bayer Healthcare, CSL Behring, Novo Nordisk, Sanofi, Pfizer Inc., among others.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2249
For the purpose of this report, Reports and Data has segmented the Hemophilia market on the basis of type, product type, treatment type, therapy type, and region:
Type (Revenue, USD Million; 2016–2026)
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Product (Revenue, USD Million; 2016–2026)
- Plasma derived coagulation factor concentrates
- Factor VIII
- Factor IX
- Factor XII
- Activated prothrombin complex concentrate
- Von Willebrand factor
- Recombinant coagulation factor concentrates
- Factor VIII
- Factor IX
- Von Willebrand factor
- Desmopressin
- Antifibrinolytic agents
- Others
Treatment Type (Revenue, USD Million; 2016–2026)
- Prophylactic
- On-Demand
Therapy Type (Revenue, USD Million; 2016–2026)
- Replacement Therapy
- Immune Tolerance Induction Therapy
- Gene Therapy
Regional Outlook (Revenue in USD Million; 2016–2026)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- The Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt
- Latin America
- Brazil
- Mexico
- Argentina
- Columbia
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2249
Key Questions Answered by the Report:
- What are the key growth driving and restraining factors of the Hemophilia market?
- What are key opportunities and growth prospects of the Hemophilia industry is expected to witness over the forecast period?
- Who are the prominent players operating in the market? What are the key strategies adopted by these companies?
- Which region is expected to dominate the market growth over the forecast period?
- Which segments are expected to register lucrative growth over the forecast period?
- What are the key outcomes of SWOT analysis and Porter’s Five Forces analysis?
Thank you for reading our report. Please connect with us to know more about the report or for requesting customization of the report. Our team will ensure the report is best suited to meet your requirements.
Explore Reports and Data’s Prime Analysis of the global Healthcare & Pharmaceutical Industry:
Diabetes Injection Pens Market @ https://www.google.sc/url?q=https://www.reportsanddata.com/report-detail/diabetes-injection-pens-market
Artificial Pancreas Device System (APDS) Market @ https://www.google.ms/url?q=https://www.reportsanddata.com/report-detail/artificial-pancreas-device-system-apds-market
Disposable Laparoscopic Instruments Market @ https://www.google.gy/url?q=https://www.reportsanddata.com/report-detail/disposable-laparoscopic-instruments-market
Recombinant Human Serum Albumin Market @ https://www.google.nu/url?q=https://www.reportsanddata.com/report-detail/recombinant-human-serum-albumin-market
Healthcare RCM Outsourcing Market @ https://www.google.fr/url?q=https://www.reportsanddata.com/report-detail/healthcare-rcm-outsourcing-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: [email protected]
Read Full Press Release: https://www.reportsanddata.com/press-release/global-hemophilia-market
The post Hemophilia Market Size To Reach USD 16.84 Billion By 2026 – Reports and Data first appeared on News Degree | Hub for Latest and Trending News from Around the Globe.
Related Posts
